Bibliografía del artículo
1. Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929-36.
2. McGarry KA, Kiel DP. Postmenopausal osteoporosis: strategies for preventing bone loss, avoiding fracture. Postgraduate Med 2000; 108:79-91.
3. Frost HM. Emerging views about "osteoporosis" bone health strength fragility, and their determinants. J Bone Miner Metab 2002; 20:319-25.
4. Kanis JA, Delmas P, Burckhardt P. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int 1997; 390:46.
5. Gregg EW, Kriska AM, Salamone LM. The epidemiology of quantitative ultrasound: a review of the relationship with bone mass, osteoporosis and fracture risk. Osteoporosis Int 1997; 7:89-99.
6. Zárate A, Basurto L, Saucedo R. Paradoja endocrinológica: los hombres necesitan estrógenos y las mujeres andrógenos. Ciencia 2003; 51:5-11.
7. Bland R. Steroid hormone receptor expression and action in bone. Clin Science 2000; 98:217-40.
8. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285:2891-97.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
10. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999; 6:273-76.
11. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis Int 2003; 14:814-22.
12. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85:2197-2202.
13. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators. Mechanisms of action an application to clinical practice. New Eng J Med 2003; 348:618-629.
14. Speroff L, Clarkson TB. Is tibolone a viable alternative to hormone therapy? Contemporary Ob Gyn 2003; 48:54-68.
15. Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-41.
16. Zárate A, Hernández M, Morán C, et al. El enfoque moderno de la osteoporosis. Rev Fac Med UNAM 2003; 46:49-51.
17. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308:1081-82.
18. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109:267-76.
19. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18:1932-41.
20. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 459-468.
21. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in stablished postmenopausal vertebral osteoporosis, a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87:2060-2066.
22. Marcus R, Wong M, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002; 23:16-37.
23. LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139:97-101.
24. Kaufman JM, Johnell O, Badie E et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000; 59:765-772.
25. Amin S, Zhang Y, Felson DT et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119:426-433.
26. Liu PY, Swerdloff RS, Veldhuis JD. The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. JH Clin Endocrinol Metab 2004; 89:4789-4796.
27. Zárate A, MacGregor C, Basurto L. Fundamento del manejo de la osteoporosis en la menopausia para evitar el consumismo diagnóstico y terapéutico. Gac Méd Méx 1999; 135:535-539.
28. Marshall D. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254-9.
29. Bikle D. Biochemical markers in the assessment of bone disease. Am J Med 1997; 103:427-36.
30. Basurto L, Saucedo R, Zárate A. Marcadores bioquímicos de remodelación ósea. Rev Med IMSS 2002; 40:193-6.